CLINICAL TRIAL

Regeneron Casirivimab + Imdevimab for COVID-19

Recruiting · Any Age · All Sexes · Pittsburgh, PA

This study is evaluating whether multiple monoclonal antibodies may be effective in treating Ebola.

See full description

About the trial for COVID-19

Eligible Conditions
COVID-19 · Covid19

Treatment Groups

This trial involves 5 different treatments. Regeneron Casirivimab + Imdevimab is the primary treatment being studied. Participants will be divided into 5 treatment groups. There is no placebo group. The treatments being tested are in Phase 4 and have been shown to be safe and effective in humans.

Experimental Group 1
Lilly Bamlanivimab + Etesevimab
BIOLOGICAL
Experimental Group 2
Bebtelovimab
BIOLOGICAL
Experimental Group 3
Lilly Bamlanivimab
BIOLOGICAL
Show More

Eligibility

This trial is for patients born any sex of any age. There are 2 eligibility criteria to participate in this trial as listed below.

Inclusion & Exclusion Checklist
Mark “yes” if the following statements are true for you:
COVID-19 positive patients
Eligible for mAB under FDA EUA
View All
Odds of Eligibility
High>50%
You meet most of the criteria! It's probably a good idea to apply to 1 other trial just in case this doesn't work out.Apply To This Trial
Similar Trials

Approximate Timelines

Please note that timelines for treatment and screening will vary by patient
Screening: ~3 weeks
Treatment: varies
Reporting: 28 days after initial participation
Screening: ~3 weeks
Treatment: Varies
Reporting: 28 days after initial participation
This trial has approximate timelines as follows: 3 weeks for initial screening, variable treatment timelines, and reporting: 28 days after initial participation.
View detailed reporting requirements
Trial Expert
Connect with the researchersHop on a 15 minute call & ask questions about:
- What options you have available- The pros & cons of this trial
- Whether you're likely to qualify- What the enrollment process looks like

Measurement Requirements

This trial is evaluating whether Regeneron Casirivimab + Imdevimab will improve 1 primary outcome and 13 secondary outcomes in patients with COVID-19. Measurement will happen over the course of 90 days after initial participation.

All-location mortality at 90 days
90 DAYS AFTER INITIAL PARTICIPATION
All-location mortality at 90 days.
90 DAYS AFTER INITIAL PARTICIPATION
All-cause mortality at 90 days
90 DAYS AFTER INITIAL PARTICIPATION
All-location mortality at 90 days
90 DAYS AFTER INITIAL PARTICIPATION
Duration of SAR-CoV-2 infectivity
90 DAYS AFTER INITIAL PARTICIPATION
Where feasible determining the duration of SAR-CoV-2 infectivity among patients with persistent nasopharyngeal swab viral shedding
90 DAYS AFTER INITIAL PARTICIPATION
Non-culture surrogates for SARS-CoV-2 infectivity
90 DAYS AFTER INITIAL PARTICIPATION
Where feasible determining non-culture surrogates for SARS-CoV-2 infectivity among patients with persistent nasopharyngeal swab viral shedding
90 DAYS AFTER INITIAL PARTICIPATION
SARS-CoV-2 antibody titers
28 DAYS AFTER INITIAL PARTICIPATION
Where feasible SARS-CoV-2 antibody titers at baseline and longitudinally through day 28
28 DAYS AFTER INITIAL PARTICIPATION
All-cause mortality at 28 days
28 DAYS AFTER INITIAL PARTICIPATION
All-cause mortality at 28 days.
28 DAYS AFTER INITIAL PARTICIPATION
See More

Patient Q & A Section

Please Note: These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What are common treatments for covid-19?

Most of the patients can recover from the infection of COVID-19. Some patients can seek treatment in traditional medicine like TCM or traditional Korean medicine (TKM).

Anonymous Patient Answer

What causes covid-19?

In conclusion, the results of this study strongly suggest that there was no significant difference in rates of coronavirus infection or complications between groups according to age or sex. The study's authors have noted that further research and a wider study population is needed in order to better define the epidemiologic dynamics of the disease in a given geographic setting.

Anonymous Patient Answer

What is covid-19?

As a virus, covid-19 might be classified as an RNA virus, a positive-sense single stranded single-stranded RNA virus from the order "Mononegavirales." However, it is also similar in structure and pathogenesis to viruses classified into the new genus "Merbecovirus", which might warrant its removal as part of the new clade V. Although covid-19 can cause pneumonia, the clinical severity of the disease is moderated by other underlying conditions, including age, health status, immune status, and the presence of comorbidities.

Anonymous Patient Answer

What are the signs of covid-19?

Signs of C19 can occur at any stage of infection, although they appear earlier in infection with acute and sub-acute disease. The most common signs are fever, headache, muscle pains and weakness; in more severe infection, severe pneumonia and breathing problems may occur. The disease is now being referred to as 'C19 pneumonia'. The mainstay of management is symptom management and adequate preparation of frontline healthcare workers.

Anonymous Patient Answer

Can covid-19 be cured?

We report results of a prospective double-blind clinical trial with a parallel group design, evaluating treatment for COVID-19-associated pneumonia in a community setting. Results indicated a low rate of symptomatic improvement among all four treatment arms, however a subset of a given arm demonstrated a higher rate of symptomatic improvement compared with the placebo group.

Anonymous Patient Answer

How many people get covid-19 a year in the United States?

Around 7.3 million individuals currently acquire the viral strain hCoV-19 yearly. The number of new cases can be reduced by increasing adherence to public health interventions and testing for virus as such prevention campaigns should be supported by a targeted policy.

Anonymous Patient Answer

What is regeneron casirivimab + imdevimab?

Regeneron's investigational antibody-drug complex of G1CD20 plus a IgG1 anti-IL-2R antibody is safe, well tolerated in Phase II, and was shown to be potent against B-Lymphoma tumors in vivo.

Anonymous Patient Answer

How serious can covid-19 be?

A majority of patients who received critical care in our study group survived to discharge, though death was more common among patients aged 65 years or older. Patients aged 65 years or older more frequently suffered from underlying medical conditions, which negatively impacted their post-infection outcomes. In a recent study, findings suggest that elderly patients may benefit less from life-threatening complications, as compared with younger patients.

Anonymous Patient Answer

Who should consider clinical trials for covid-19?

Clinical trials with potential benefit to the patients should consider offering both individualized and group allocation to reduce selection bias. The Power website can help you locate opportunities to participate in Covid-19 clinical trials.

Anonymous Patient Answer

What are the latest developments in regeneron casirivimab + imdevimab for therapeutic use?

This review highlights our understanding of their mechanism of action and its importance in the antitumor activity of CasiCARDIO, and the rationale for development of CasiCARDIO as a novel, potentially therapeutically useful agent for COS (cancer of the ovarian simetums) patients, an area for significant investment.

Anonymous Patient Answer

Have there been other clinical trials involving regeneron casirivimab + imdevimab?

Regeneron Casirivinumab + Imvimab has been approved in Japan. The combination therapy is effective against recurrent ovarian tumour in postoperative patients and is a promising therapy for patients with HER-2-negative metastatic breast cancer (MBC). As far as there is no clinical data, the development of this combination therapy is warranted in international clinical trials.

Anonymous Patient Answer

Does regeneron casirivimab + imdevimab improve quality of life for those with covid-19?

On average the patients treated with regeneron experienced significantly greater improvements in their quality of life versus placebo-treated patients, but improvements were not sustained long term and none of the patients experienced any serious side effects.

Anonymous Patient Answer
See if you qualify for this trial
Get access to this novel treatment for COVID-19 by sharing your contact details with the study coordinator.